Literature DB >> 21178982

In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11C]-(+)-PHNO.

Ragy R Girgis1, Xiaoyan Xu, Nobumi Miyake, Balu Easwaramoorthy, Roger N Gunn, Eugenii A Rabiner, Anissa Abi-Dargham, Mark Slifstein.   

Abstract

Measuring the in vivo occupancy of antipsychotic drugs at dopamine D(2) and D(3) receptors separately has been difficult because of the lack of selective radiotracers. The recently developed [(11)C]-(+)-PHNO is D(3)-preferring, allowing estimates of the relative D(2) and D(3) binding of antipsychotic drugs. We used positron emission tomography (PET) imaging in baboons with [(11)C]-(+)-PHNO to examine the binding of clozapine and haloperidol to D(2) and D(3) receptors. Four animals were scanned with dynamically acquired PET and arterial plasma input functions. Test and retest scans were acquired in single scanning sessions for three subjects to assess the reproducibility of [(11)C]-(+)-PHNO scans. Four additional scans were acquired in each of three subjects following single doses of antipsychotic drugs (clozapine 0.5534 mg/kg, haloperidol 0.0109 mg/kg, two administrations per drug per subject) and compared with baseline scans. The percent change in binding (ΔBP(ND)) following challenges with antipsychotic drugs was measured. A regression model, based on published values of regional D(2) and D(3) fractions of [(11)C]-(+)-PHNO BP(ND) in six brain regions, was used to infer occupancy at D(2) and D(3) receptors. BP(ND) following antipsychotic challenge decreased in all regions. Estimated D(2) : D(3) selectivity was 2.38 for haloperidol and 5.25 for clozapine, similar to published in vitro values for haloperidol (3.03), but slightly higher for clozapine (2.82). These data suggest that acute doses of clozapine and haloperidol bind to D(3) receptors in vivo, and that the lack of D(3) occupancy by antipsychotics observed in some recent imaging studies may be because of other phenomena.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178982      PMCID: PMC3055723          DOI: 10.1038/npp.2010.228

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  23 in total

1.  Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.

Authors:  S Kapur; P Seeman
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Derivation of [(11)C]WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions.

Authors:  M Slifstein; R V Parsey; M Laruelle
Journal:  Nucl Med Biol       Date:  2000-07       Impact factor: 2.408

3.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons.

Authors:  P Seeman; T Lee
Journal:  Science       Date:  1975-06-20       Impact factor: 47.728

5.  Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.

Authors:  Graham Searle; John D Beaver; Robert A Comley; Massimo Bani; Andri Tziortzi; Mark Slifstein; Manolo Mugnaini; Cristiana Griffante; Alan A Wilson; Emilio Merlo-Pich; Sylvain Houle; Roger Gunn; Eugenii A Rabiner; Marc Laruelle
Journal:  Biol Psychiatry       Date:  2010-08-15       Impact factor: 13.382

Review 6.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

7.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

8.  Clinical pharmacokinetics of clozapine in chronic schizophrenic patients.

Authors:  Y F Cheng; T Lundberg; U Bondesson; L Lindström; J Gabrielsson
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 9.  Atypical antipsychotics: mechanism of action.

Authors:  Philip Seeman
Journal:  Can J Psychiatry       Date:  2002-02       Impact factor: 4.356

10.  Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys.

Authors:  Hideo Tsukada; Katsumasa Miyasato; Takeharu Kakiuchi; Shingo Nishiyama; Norihiro Harada; Edward F Domino
Journal:  Synapse       Date:  2002-09-15       Impact factor: 2.562

View more
  20 in total

Review 1.  Positron emission tomography molecular imaging for drug development.

Authors:  Paul M Matthews; Eugenii A Rabiner; Jan Passchier; Roger N Gunn
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

2.  Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.

Authors:  David Matuskey; Patrick Worhunksy; Elizabeth Correa; Brian Pittman; Jean-Dominique Gallezot; Nabeel Nabulsi; Jim Ropchan; Venkatesh Sreeram; Rohit Gudepu; Edward Gaiser; Kelly Cosgrove; Yu-Shin Ding; Marc N Potenza; Yiyun Huang; Robert T Malison; Richard E Carson
Journal:  Neuroimage       Date:  2016-02-11       Impact factor: 6.556

3.  Exploring the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO.

Authors:  Fernando Caravaggio; Jun Ku Chung; Philip Gerretsen; Gagan Fervaha; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Alan Wilson; Ariel Graff-Guerrero
Journal:  Soc Neurosci       Date:  2016-02-29       Impact factor: 2.083

4.  Characterization of extrastriatal D2 in vivo specific binding of [¹⁸F](N-methyl)benperidol using PET.

Authors:  Sarah A Eisenstein; Jon M Koller; Marilyn Piccirillo; Ana Kim; Jo Ann V Antenor-Dorsey; Tom O Videen; Abraham Z Snyder; Morvarid Karimi; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey
Journal:  Synapse       Date:  2012-05-15       Impact factor: 2.562

5.  Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry.

Authors:  Fernando Caravaggio; Enzo Scifo; Etienne L Sibille; Sergio E Hernandez-Da Mota; Philip Gerretsen; Gary Remington; Ariel Graff-Guerrero
Journal:  Exp Eye Res       Date:  2018-06-05       Impact factor: 3.467

6.  The relationship between subcortical brain volume and striatal dopamine D2/3 receptor availability in healthy humans assessed with [11 C]-raclopride and [11 C]-(+)-PHNO PET.

Authors:  Fernando Caravaggio; Jun Ku Chung; Eric Plitman; Isabelle Boileau; Philip Gerretsen; Julia Kim; Yusuke Iwata; Raihaan Patel; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Hum Brain Mapp       Date:  2017-07-28       Impact factor: 5.038

7.  A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia.

Authors:  Ragy R Girgis; Andy Forbes; Anissa Abi-Dargham; Mark Slifstein
Journal:  Neuropsychopharmacology       Date:  2019-12-17       Impact factor: 7.853

8.  Lack of age-dependent decrease in dopamine D3 receptor availability: a [(11)C]-(+)-PHNO and [(11)C]-raclopride positron emission tomography study.

Authors:  Shinichiro Nakajima; Fernando Caravaggio; Isabelle Boileau; Jun K Chung; Eric Plitman; Philip Gerretsen; Alan A Wilson; Sylvain Houle; David C Mamo; Ariel Graff-Guerrero
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-10       Impact factor: 6.200

Review 9.  Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.

Authors:  Gerhard Gross; Karsten Wicke; Karla U Drescher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-06       Impact factor: 3.000

10.  Parametric Imaging and Test-Retest Variability of ¹¹C-(+)-PHNO Binding to D₂/D₃ Dopamine Receptors in Humans on the High-Resolution Research Tomograph PET Scanner.

Authors:  Jean-Dominique Gallezot; Ming-Qiang Zheng; Keunpoong Lim; Shu-fei Lin; David Labaree; David Matuskey; Yiyun Huang; Yu-Shin Ding; Richard E Carson; Robert T Malison
Journal:  J Nucl Med       Date:  2014-04-14       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.